CADL/ 10/28/2025 · 10:33 AM Stephens Initiates Overweight Coverage on Candel Therapeutics, Citing Transformative Pipeline and Limited Competition Candel earned a $15 stock rating. Its key drug, CAN-2409, is seen as transformative because it improves current treatments.